ImmuCell (ICCC) Q4 2025 TU earnings summary

Executive summary

• Strategic focus shifted to prioritize First Defense, suspending further investment in Re-Tain due to regulatory setbacks and resource allocation considerations.

• Achieved a near-record sales quarter in Q4 2025, with strong domestic growth and operational improvements.

• Domestic sales grew 8.7% in Q4 and 6.5% for the year, while international sales declined 52.6% in Q4 and 9.6% for the year.

• Tri-Shield sales surged 41.3% in Q4 and 26.5% for the year, offsetting declines in Dual-Force and other sales.

• Leadership transition with the retirement of the long-serving CEO.

Financial highlights

• Q4 2025 product sales were $7.6 million, down 1.6% year-over-year, while full-year 2025 sales reached $27.6 million, up 4.3%.

• Domestic Q4 sales: $7.0 million (up 8.7%); international Q4 sales: $0.6 million (down 52.6%).

• Tri-Shield Q4 sales: $6.0 million (up 41.3%); Dual-Force Q4 sales: $1.5 million (down 53.7%).

• Q4 2025 included a non-cash impairment write-down of $2.9 million related to Re-Tain assets.

• Inventory write-down of $600,000 for unsuitable colostrum.

Outlook and guidance

• Continued focus on expanding First Defense capacity and operational excellence, with further details on capacity expansion to be provided in coming quarters.

• Expectation of maintaining seasonality in sales, with Q4 and Q1 as peak quarters.

• Ongoing evaluation of funding options for capital investments, including possible capital raises, loans, or operating cash flow.

• Manufacturing improvements increased lyophilization output by over 15% in 2025, with further gains expected in 2026.

• Sales force expanded by 50% to support commercial growth.